gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ATRAHealthcareBiotechnology

Atara Biotherapeutics, Inc (ATRA)

$7.92−5.44%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$7.92▼ 35.60% in range
Nov 4, 2025Low $4.18 · High $18.09Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Atara Biotherapeutics closed at $7.92 on Nov 5, down 5.44%, 56.2% below its 52-week closing high. Volume of 15.0K shares was 0.62× its 20-day average (below normal).

Split-adjusted performance: -15.5% over one month, -20.3% over six months, -35.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $630K, down 96.4% from a year earlier, with a net margin of -767.3%.

Short interest was 350.3K shares at the Oct 15 settlement, up 8.8% from the prior report (11.2% of float, 8.7 days to cover).

Market cap$79.4M10.0M shares
Revenue · quarter$630.0K−96.4% YoY
Diluted EPS$-0.32−268.4% YoY
P/E · TTM—P/S 12.8×
Net margin-767.3%Gross 69.7%
Dividend yieldNone
52-week range4.18 – 18.09−56.2% from high
Volume15.0K0.62× 20-day avg
Volatility · 60d65.7%Annualised
Short % of float11.2%8.7 days to cover
Net cash$9.9MCash $9.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.2%1M −15.5%3M −6.3%6M −20.3%YTD −56.2%1Y −35.6%3Y −75.5%5Y −98.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum53
Revenue growth12
Net margin33
Value (low P/E)—
Size32

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →
Shares short350.3K+8.8% vs prior
Days to cover8.7Settled Oct 15
% of float11.2%
Short vol. 10d51.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ATRAAtara Biotherapeutics$7.92−5.44%−20.3%−96.4%−767.3%—$79.4M
TNYATenaya Therapeutics$0.3400−8.08%−59.9%—−3909.3%—$77.5MCompare
TVGNTevogen$5.31−7.17%−29.0%———$89.0MCompare
CSBRChampions Oncology$4.79−0.83%−20.0%+8.8%−2.8%—$66.7MCompare
NMRANeumora Therapeutics$0.5111−9.70%−73.7%———$96.0MCompare
LENZLENZ Therapeutics$3.08−10.98%−68.3%−72.9%−915.2%—$96.8MCompare
BDTXBlack Diamond Therapeutics$1.69−11.05%−37.9%———$97.1MCompare
AVXLAnavex Life Sciences$1.11−12.30%−64.6%———$102.4MCompare
CGTXCognition Therapeutics$0.6405−6.26%−44.8%———$60.9MCompare

News about Atara Biotherapeutics

All news →
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRAGlobeNewswire Inc. · May 19, 2026▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · May 18, 2026▼ NegativeDEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc. · May 14, 2026▼ NegativeATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc. · May 14, 2026▼ NegativeDeadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc. · May 12, 2026▼ Negative

Quick answers

What does Atara Biotherapeutics do?
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases.
What is ATRA's market cap?
$79.45M, based on the Nov 5 close of $7.92.
Does Atara Biotherapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ATRA is sold short?
350.3K shares, 11.2% of float, as of Oct 15, 2026.
What sector is ATRA in?
Healthcare, in the Biotechnology industry.

About Atara Biotherapeutics

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

HQ: Thousand Oaks, CA10 employeesListed Oct 16, 2014atarabio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology